Cardamonin: A new player to fight cancer via multiple cancer signaling pathways

Basit Öğe Kaydı
dc.authoridSelamoglu, Zeliha/0000-0001-9056-6435
dc.authoridShah, Muhammad Ajmal/0000-0003-3471-184X
dc.authoridRiaz, Ammara/0000-0001-5025-9182
dc.contributor.authorNawaz, Javaria
dc.contributor.authorRasul, Azhar
dc.contributor.authorShah, Muhammad Ajmal
dc.contributor.authorHussain, Ghulam
dc.contributor.authorRiaz, Ammara
dc.contributor.authorSarfraz, Iqra
dc.contributor.authorZafar, Saba
dc.date.accessioned2024-11-07T13:32:04Z
dc.date.available2024-11-07T13:32:04Z
dc.date.issued2020
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractNature's pharmacy has undoubtedly served humans as an affordable and safer health-care regime for a long times. Cardamonin, a chalconoid present in several plants has been known for a longtime to have beneficial properties towards human health. In this review, we aimed to highlight the recent advances achieved in discovering the pharmacological properties of cardamonin. Cardamonin is cardamom-derived chalcone, which plays a role in cancer treatment, immune system modulation, inflammation and pathogens killing. Through the modulation of cellular signaling pathways, cardamonin activates cell death signal to induce apoptosis in malignant cells that results in the inhibition of cancer development. Moreover, cardamonin arrests cell cycle by altering the expression of regulatory proteins during malignant cells division. Due to its relatively selective cytotoxic potential against host malignant cells, cardamonin is emerging as a promising novel experimental anticancer agent. The potential of cardamonin to target various signaling molecules, transcriptional factors, cytokines and enzymes, such as mTOR, NF-kappa B, Akt, STAT3, Wnt/beta-catenin and COX-2 enhances the opportunity to explore it as a new multi-target therapeutic agent. The pharmacokinetic and biosafety profile of cardamonin favor it as a potentially safe biomolecule for pharmaceutical drug development.
dc.description.sponsorshipNagai Foundation Tokyo, Japan [NFT-R-2018]; TWAS-COMSTECH Research Grant [17-180 RG/PHA/AS_C]; NRPU Research Grants [8381/Punjab/NRPU/RD/HEC/2017, 8382/Punjab/NRPU/RD/HEC/2017]
dc.description.sponsorshipThis study was supported by the research grant The Nagai Foundation Tokyo, Japan (NFT-R-2018), TWAS-COMSTECH Research Grant (No._17-180 RG/PHA/AS_C) and NRPU Research Grants (8381/Punjab/NRPU/R&D/HEC/2017, 8382/Punjab/NRPU/R&D/HEC/2017). We would also like to thank Higher Education Commission (HEC), Pakistan for providing access to related papers from various journals. The authors wish to thank Dr. Samiullah KHAN and Mr. John Constable for assistance with the English.
dc.identifier.doi10.1016/j.lfs.2020.117591
dc.identifier.issn0024-3205
dc.identifier.issn1879-0631
dc.identifier.pmid32224026
dc.identifier.scopus2-s2.0-85082512175
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.lfs.2020.117591
dc.identifier.urihttps://hdl.handle.net/11480/15204
dc.identifier.volume250
dc.identifier.wosWOS:000530710200032
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherPergamon-Elsevier Science Ltd
dc.relation.ispartofLife Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20241106
dc.subjectCardamonin
dc.subjectChalcone
dc.subjectAnticancer
dc.subjectCardamom
dc.titleCardamonin: A new player to fight cancer via multiple cancer signaling pathways
dc.typeReview Article

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu